Analysis of Segments and Major Growth Areas in the Monoclonal Antibodies Market for Veterinary Health

The veterinary health sector is witnessing remarkable advancements with the growing adoption of monoclonal antibodies (mAbs) as therapeutic solutions. As pet care and livestock health continue to gain attention, the monoclonal antibodies market is poised for substantial expansion, driven by innovations and increasing investments in specialized treatments. Below is an overview of the market's size, key players, emerging trends, and important segments shaping this promising industry.

Projected Growth and Market Size of Monoclonal Antibodies in Veterinary Health
The monoclonal antibodies segment within veterinary health is forecasted to experience rapid growth, reaching a valuation of $1.85 billion by 2030. This expansion corresponds to an impressive compound annual growth rate (CAGR) of 14.8%. Several factors contribute to this trajectory, including technological progress in monoclonal antibody engineering, greater use of therapies tailored to specific animal species, increased funding in veterinary oncology and dermatology, the rise of personalized veterinary medicine, and the broadening of veterinary healthcare infrastructure on a global scale. Key market trends expected during this period involve the growing use of mAbs in canine cancer treatments, expanded applications in autoimmune disease management for dogs, development in veterinary dermatology, greater adoption of targeted pain relief therapies, and species-specific therapies for cats, horses, and livestock.

Download a free sample of the monoclonal antibodies in veterinary health market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Market Participants in Monoclonal Antibodies for Veterinary Health
The market landscape features a wide array of prominent companies dedicated to advancing monoclonal antibody therapies in veterinary medicine. Notable players include Zoetis Inc, Boehringer Ingelheim International GmbH, MSD Animal Health, Elanco Animal Health Incorporated, Heska Corporation, Ceva Santé Animale S.A., Biogénesis Bagó S.A., PetMedix Ltd, Merck & Co Inc, Virbac SA, Kindred Biosciences Inc, Dechra Pharmaceuticals, Vetigenics, Akston Biosciences Corporation, MabGenesis Inc, IDEXX Laboratories Inc, Nexvet Biopharma, Epitopix LLC, Indian Immunologicals Ltd, Vetoquinol, Phibro Animal Health, Norbrook Laboratories, AnimalCare, Eco Animal Health, Venkys, Hester Biosciences Limited, and ImmuCell.

Noteworthy Industry Acquisition Enhancing Biotechnology Efforts
In January 2024, Ceva Santé Animale, a France-based animal health company, announced its acquisition of Scout Bio Inc., a US biotechnology firm known for pioneering monoclonal antibody therapies targeting chronic conditions in pets. This strategic move, for an undisclosed sum, is designed to accelerate Ceva Santé's global biotechnology initiatives by leveraging Scout Bio's expertise in gene therapy and monoclonal antibody innovation, ultimately aiming to improve treatment options for chronic diseases in animals.

View the full monoclonal antibodies in veterinary health market report:
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-in-veterinary-health-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Innovative Trends Driving the Monoclonal Antibodies Veterinary Market
Key companies are actively developing cutting-edge therapeutic solutions such as anti-NGF monoclonal antibody treatments, which target nerve growth factor to alleviate chronic pain and inflammation in animals. This approach offers a novel option for managing debilitating conditions affecting pets. For example, in May 2023, Zoetis secured FDA approval for Librela (bedinvetmab injection), the first monoclonal antibody approved for controlling osteoarthritis-associated pain in dogs. Librela is administered monthly and works by blocking NGF to reduce pain signals reaching the brain, marking a significant breakthrough in veterinary pain management.

Additional advancements include Apoquel Chewable, also by Zoetis, which is the first chewable drug approved for treating allergic itch and inflammation in dogs aged one year and above. These innovations highlight the market's ongoing commitment to providing effective and targeted therapies that improve the quality of life for animals suffering from chronic ailments.

Detailed Segmentation of the Monoclonal Antibodies in Veterinary Health Market
This market is broken down into several critical segments to better understand its scope:
1) By Product: Monoclonal Antibodies (mAbs), Glucocorticoids, Antihistamines, Immunosuppressants, and Other Products
2) By Animal Type: Dogs, Cats, Horses, Livestock, and Other Animals
3) By Indication: Allergic Skin Disease, Autoimmune Disorders, Infectious Diseases, Cancer or Tumor Therapy, and Other Indications
4) By Route of Administration: Injectable, Oral, and Topical
5) By Distribution Channel: Veterinary Clinics, Specialized Animal Hospitals, Retail Pharmacies, Online Pharmacies, and Other Distribution Channels.

Subcategories within these segments include specific monoclonal antibodies such as Lokivetmab, Felvetmab, investigational mAbs, and equine-specific antibodies. Glucocorticoids cover medications like Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, and Triamcinolone. Antihistamines include Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, and Chlorpheniramine. Immunosuppressants comprise Cyclosporine, Tacrolimus, Azathioprine, and Mycophenolate Mofetil. Other products feature essential fatty acid supplements, medicated shampoos and sprays, allergen-specific immunotherapy, skin barrier repair creams, nutraceuticals, and probiotics.

This detailed segmentation helps provide a clearer picture of the diverse therapeutic options and delivery methods within the monoclonal antibodies veterinary health market.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.